Jacqz-Aigrain, E.M.

morphine patient children model concentration 10 days neonate clearance pharmacogenetic mutation bodyweight distribution cancer study postnatal age preterm population glucuronidation european medicines agency pharmacogenomic metabolite warfarin allele . med factor covariate infant result pharmacokinetic elimination influence trial postnatal tumor toxicity tacrolimu genotype formation response variant dosing science cyp 2c volume loading dose preterm neonates value *5701 hla-b 3 years tamoxifen european pharmacokinet postmenstrual age effect saliva sample snps information equation medicine statin parameter function gefitinib prediction university polymorphism serum maintenance dose /pharmacogenomic morphine -6-glucuronide table presence clopidogrel treatment disease blood non-small-cell lung cancer figure prediction distribution errors range